Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma: Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen

American Journal of Surgical Pathology

Volumn 20, Issue 5, 1996, Pages 553-562

  Kitamura, Hitoshi ^a,e   Kameda, Yoichi ^b   Nakamura, Nobuo ^c   Inayama, Yoshiaki ^a   Nakatani, Yukio ^a   Shibagaki, Tokuhiko ^d   Ito, Takaaki ^a   Hayashi, Hiroyuki ^a   Kimura, Hirokazu ^a   Kanisawa, Masayoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^d Kanagawa Cardiovascular and Respiratory Center   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Atypical adenomatous hyperplasia; Bronchoalveolar lung carcinoma; Carcinoembryonic antigen; Immunohistochemistry; Morphometry; p53

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CELL NUCLEUS; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; HYPERPLASIA; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9244257263     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199605000-00002     Document Type: Article

References (35)

1. Artacho-Pérula E, Roldán-Villalobos R, Martínez-Cuevas JF, López-Rubio F. Nuclear quantitative grading by discriminant analysis of renal cell carcinoma samples: a patient survival evaluation. J Pathol 1994;173:105-14.
2. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchoalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994;73:1163-70.
3. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
4. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143:199-210.
5. Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szanto AJP. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 1991;139:839-45.
6. Clayton F. The spectrum and significance of bronchoalveolar carcinomas. Pathol Annu 1988;23:361-94.
7. Colby TV, Koss MK, Travis WD. Bronchoalveolar carcinoma. In: Tumors of the lower respiratory tract. Washington, DC: Armed Forces Institute of Pathology, 1995:203-34 (Atlas of tumor pathology, 3rd series, fasc. 13).
8. Fleege JC, van Diest PJ, Baak JPA. Reliability of quantitative pathological assessments, standards, and quality control. In: Baak JPA, ed. Manual of quantitative pathology in cancer diagnosis and prognosis. Berlin: Springer-Verlag, 1991;151-81.
9. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry?-revisited! J Pathol 1994;172:1-4.
10. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
11. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 1992;83:101-6.
12. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
13. Kerr KM, Carey FA, King G, Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol 1994;174:249-56.
14. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early-stage lesions of bronchoalveolar lung carcinoma. Am J Pathol 1995;146:876-87.
15. Kodama T, Biyajima S, Watanabe S, Shimosato Y. Morphometric study of adenocarcinomas and hyperplastic epithelial lesions in the peripheral lung. Am J Clin Pathol 1986;85:146-51.
16. Kodama T, Nishiyama H, Nishiwaki Y, et al. Histopathological study of adenocarcinoma and hyperplastic epithelial lesions of the lung. Lung Cancer 1988;28:325-33.
17. Liebow AA. Bronchoalveolar carcinoma. Adv Intern Med 1960;10:329-58.
18. Miller RR, Nelems B, Evans KG, Müller NL, Ostrow DN. Glandular neoplasia of the lung: a proposed analogy to colonic tumors. Cancer 1988;61:1009-14.
19. Miller RR. Bronchioloalveolar cell adenomas. Am J Surg Pathol 1990;14:904-12.
20. Mori M, Chiba R, Takahashi T. Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma: characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer 1993;72:2331-40.
21. Morinaga S, Shimosato Y. Pathology of minute adenocarcinoma in the peripheral lung. Pathol Clin Med Jpn 1987;5: 74-80.
22. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990;114:363-8.
23. Nakayama H, Noguchi M, Tsuchiya R, Kodama T, Shimosato Y. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol 1990;3:314-20.
24. Ohshima S, Shimizu Y, Takahama M. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchoalveolar cell hyperplasia of human lung. Virchows Arch 1994;424:129-34.
25. Sato T. Discriminant analysis. In: Yanai H, Takagi H, eds. Handbook of multivariate analysis. Kyoto: Gendaisugaku, 1991:126-59.
26. Shimosato Y, Kodama T. Low grade malignant and benign tumors. In: McDowell EM, ed. Current problems in tumour pathology. Lung carcinomas. New York: Churchill Livingstone, 1987:310-29.
27. Shimosato Y, Noguchi M, Matsuno Y. Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer 1993;9:99-108.
28. Skaarland E. Nuclear size and shape of epithelial cells from the endometrium: lack of value as a criterion for differentiation between normal, hyperplastic, and malignant conditions. J Clin Pathol 1985;38:502-6.
29. Sobin L, Yesner R. Histological typing of lung tumours. International histological classification of tumours, no. 1, 2nd ed. Geneva: World Health Organization, 1981:25-6.
30. Sun NCJ, Edgington TD, Carpentier CL, McAfee W, Terry R, Bateman J. Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung. Cancer 1983; 52:1632-41.
31. Tenaud C, Negoescu A, Labat-Moleur F, Legros Y, Soussi T, Brambilla E. p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol base on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 1994;7:853-9.
32. Wachner R, Wittekind C, von Kleist S. Localisation of CEA, β-HCG, SP1, and keratin in the tissue of lung carcinomas: an immunohistochemical study. Virchows Arch Pathol Anat 1984;402:415-23.
33. Weng SY, Tsuchiya E, Kasuga T, Sugano H. Incidence of atypical bronchoalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer Virchows Arch Pathol Anat 1992;420:463-71.
34. Westra WH, Offerhaus GJA, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17:213-20.
35. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-330.